RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024
Data Summaries from Key Studies:
- Data Summaries from Key Studies:
Subgroup Analyses from the TIMELESS Trial, by Gregory Albers, M.D., presented and simultaneously published in the NEJM. - Key imaging criteria: target mismatch ratio of ≥1.8, mismatch volume of ≥15 mL, and ischemic core volume
- Data showed a median reduction of 30 minutes per patient from door-to-mechanical thrombectomy (MT) after the integration of RapidAI.
- “In the world of AI, clinical validation is paramount to instill confidence in clinician decision-making,” said Karim Karti, CEO of RapidAI.